News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
299,591 Results
Type
Article (14954)
Company Profile (294)
Press Release (284343)
Section
Business (91303)
Career Advice (156)
Deals (16116)
Drug Delivery (31)
Drug Development (53472)
Employer Resources (31)
FDA (6800)
Job Trends (5517)
News (164641)
Policy (12296)
Tag
Academia (946)
Alliances (25847)
Alzheimer's disease (774)
Approvals (6767)
Artificial intelligence (60)
Bankruptcy (103)
Best Places to Work (4687)
Biotechnology (244)
Breast cancer (59)
Cancer (596)
Cardiovascular disease (52)
Career advice (137)
Cell therapy (149)
Clinical research (42295)
Collaboration (209)
Compensation (85)
COVID-19 (1079)
C-suite (52)
Cystic fibrosis (61)
Data (629)
Diabetes (64)
Diagnostics (1624)
Earnings (32891)
Events (50263)
Executive appointments (152)
FDA (7066)
Funding (212)
Gene editing (47)
Gene therapy (127)
GLP-1 (307)
Government (1183)
Healthcare (7063)
Infectious disease (1110)
Inflammatory bowel disease (91)
IPO (7990)
Job creations (1040)
Job search strategy (133)
Layoffs (185)
Legal (2116)
Lung cancer (107)
Manufacturing (69)
Medical device (3468)
Medtech (3470)
Mergers & acquisitions (8208)
Metabolic disorders (202)
Neuroscience (955)
NextGen Class of 2024 (2115)
Non-profit (880)
Northern California (787)
Obesity (116)
Opinion (90)
Parkinson's disease (56)
Patents (47)
People (27400)
Pharmaceutical (48)
Phase I (14546)
Phase II (19470)
Phase III (12773)
Pipeline (146)
Postmarket research (985)
Preclinical (6092)
Radiopharmaceuticals (210)
Rare diseases (143)
Real estate (1862)
Regulatory (9624)
Research institute (973)
Southern California (720)
Startups (2168)
United States (6691)
Vaccines (162)
Weight loss (70)
Date
Today (55)
Last 7 days (453)
Last 30 days (1749)
Last 365 days (22031)
2024 (18661)
2023 (23971)
2022 (30256)
2021 (31145)
2020 (26604)
2019 (18343)
2018 (13442)
2017 (15641)
2016 (13742)
2015 (16812)
2014 (12453)
2013 (9312)
2012 (9526)
2011 (9709)
2010 (9315)
Location
Africa (193)
Arizona (45)
Asia (29463)
Australia (4262)
California (1777)
Canada (687)
China (153)
Colorado (64)
Connecticut (71)
Europe (43384)
Florida (194)
Georgia (51)
Illinois (112)
Indiana (51)
Kansas (58)
Maryland (272)
Massachusetts (1498)
Michigan (45)
Minnesota (97)
New Jersey (506)
New York (548)
North Carolina (389)
Northern California (787)
Ohio (71)
Pennsylvania (376)
South America (272)
Southern California (720)
Texas (179)
Washington State (196)
299,591 Results for "carrick therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts and Appoints David Sutherland, CPA, as Vice President of Finance and Controller
Carrick Therapeutics Inc. today announced the relocation of its corporate headquarters from Dublin, Ireland to Boston, Massachusetts.
June 5, 2024
·
2 min read
Press Releases
Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)
September 23, 2024
·
2 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
Carrick Therapeutics today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuraciclib (CT7001).
February 14, 2024
·
4 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer
Carrick Therapeutics today announced that the first patient has been dosed in its Phase 2 clinical trial evaluating the novel combination of Carrick’s samuraciclib (CT7001).
October 18, 2023
·
6 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer
Carrick Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating the combination of samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, and fulvestrant, an intramuscular injected selective estrogen receptor degrader (SERD), in women with HR+, HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor.
December 15, 2023
·
3 min read
Business
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
Carrick Therapeutics today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE).
July 6, 2023
·
5 min read
Genetown
Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CT7439, a novel cyclin dependent kinase 12/13 (CDK12/13) inhibitor.
September 7, 2023
·
2 min read
Press Releases
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024
·
2 min read
Genetown
Carrick Therapeutics Closes Series C Financing
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing.
December 1, 2022
·
2 min read
Press Releases
Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies
October 30, 2024
·
5 min read
1 of 29,960
Next
